26.9 C
New York
Friday, June 12, 2026

Tag: medicines

newssourceFORcompanyinformationcontent1marketreleases

Hydrofluoric Acid Market worth $5.10 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 12, 2025 /PRNewswire/ -- The report 'Hydrofluoric Acid Market by Grade , Application, and Region (Asia Pacific, North America, Europe,...

Hydrofluoric Acid Market worth $5.10 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 12, 2025 /PRNewswire/ -- The report 'Hydrofluoric Acid Market by Grade , Application, and Region (Asia Pacific, North America, Europe,...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial

During Sleep Health Week (11-15 August 2025), Australians living with insomnia are reminded that a new treatment is on the horizon – with clinical...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Boehringer Ingelheim Celebrates Next Generation of Biomedical Researchers at 2025 Veterinary Scholars Symposium

Student researchers from Mississippi State University and The Ohio State University received Boehringer Ingelheim research awards DULUTH, Ga., Aug. 11, 2025 /PRNewswire/ -- Veterinary research took...

The Galien Foundation Announces 2025 Prix Galien USA Nominees for “Best Biotechnology Product,” “Best Pharmaceutical Product” and “Best Product for Rare/Orphan Diseases”

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the...

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and...

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers